What is the recommended screening interval for Cologuard (multitarget stool DNA testing) in individuals at average risk of colorectal cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Screening Interval for Cologuard in Average-Risk Individuals

The recommended screening interval for Cologuard (multitarget stool DNA testing) is every 3 years in individuals at average risk of colorectal cancer. 1, 2

Screening Recommendations for Cologuard

Cologuard, also known as FIT-fecal DNA or multitarget stool DNA testing, is one of several recommended options for colorectal cancer screening in average-risk individuals. The test combines FIT (Fecal Immunochemical Test) with DNA markers to detect both colorectal cancer and precancerous lesions.

Effectiveness of Cologuard

  • Higher sensitivity for colorectal cancer (92.3%) compared to FIT alone (73.8%)
  • Better detection of advanced precancerous lesions (42.4%) than FIT (23.8%)
  • Slightly lower specificity (86.6%) than FIT (94.9%) 1

When to Start and Stop Screening

  • Start screening at age 45 for average-risk individuals 2, 1
  • Continue screening through age 75 for those in good health with life expectancy >10 years 2, 1
  • For ages 76-85, individualize decisions based on prior screening history, health status, and patient preferences 2
  • Discontinue screening after age 85 1

Comparing Screening Options and Intervals

Cologuard is considered a second-tier screening option by the U.S. Multi-Society Task Force on Colorectal Cancer, with first-tier options being colonoscopy every 10 years or annual FIT 2, 3.

Recommended Screening Intervals for Different Tests:

  • Colonoscopy: every 10 years
  • FIT: annually
  • FIT-fecal DNA (Cologuard): every 3 years
  • CT colonography: every 5 years
  • Flexible sigmoidoscopy: every 5 years 2, 1

Important Clinical Considerations

Follow-up for Positive Results

Any positive Cologuard test should be followed up with a diagnostic colonoscopy, regardless of the screening test used 1.

Special Populations

  • African Americans may benefit from starting screening at age 45 due to higher incidence of colorectal cancer 2, 1
  • Individuals with family history of colorectal cancer or advanced adenomas should follow different screening protocols, typically with colonoscopy starting earlier and performed more frequently 4

Common Pitfalls to Avoid

  1. Inappropriate follow-up intervals: Adhering to the 3-year interval for Cologuard is crucial; screening more frequently than recommended doesn't improve outcomes but increases costs 2

  2. Failure to follow up positive results: A positive Cologuard test requires prompt follow-up with colonoscopy 1

  3. Using Cologuard in high-risk individuals: Cologuard is intended for average-risk screening only; high-risk individuals should undergo colonoscopy-based screening 3

  4. Continuing screening beyond appropriate age: Consider discontinuing screening after age 75 in individuals who have had negative prior screening, particularly high-quality colonoscopy 2

By following these evidence-based recommendations for Cologuard screening intervals, clinicians can optimize the balance between early detection of colorectal cancer and avoiding unnecessary testing, ultimately improving patient outcomes related to morbidity and mortality from colorectal cancer.

References

Guideline

Colorectal Cancer Screening Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.